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Human Oxidation-Specific Antibodies Reduce
Foam Cell Formation and Atherosclerosis Progression
Sotirios Tsimikas, MD,* Atsushi Miyanohara, PHD,* Karsten Hartvigsen, PHD,* Esther Merki, PHD,*
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Objectives We sought to assess the in vivo importance of scavenger receptor (SR)–mediated uptake of oxidized low-density
lipoprotein (OxLDL) in atherogenesis and to test the efficacy of human antibody IK17-Fab or IK17 single-chain Fv
fragment (IK17-scFv), which lacks immunologic properties of intact antibodies other than the ability to inhibit
uptake of OxLDL by macrophages, to inhibit atherosclerosis.
Background The unregulated uptake of OxLDL by macrophage SR contributes to foam cell formation, but the importance of
this pathway in vivo is uncertain.
Methods Cholesterol-fed low-density lipoprotein receptor knockout (LDLR/) mice were treated with intraperitoneal infu-
sion of human IK17-Fab (2.5 mg/kg) 3 times per week for 14 weeks. Because anti-human antibodies developed
in these mice, LDLR//low-density lipoprotein receptor Rag 1 double-knockout mice (lacking the ability to
make immunoglobulins due to loss of T- and B-cell function) were treated with an adenoviral vector encoding
adenovirus expressed (Adv)–IK17-scFv or control adenovirus-enhanced green fluorescent protein vector intrave-
nously every 2 weeks for 16 weeks.
Results In LDLR/ mice, infusion of IK17-Fab was able to sustain IK17 plasma levels for the first 8 weeks, but these
diminished afterward due to increasing murine anti-IK17 antibody titers. Despite this, after 14 weeks, a 29%
decrease in en face atherosclerosis was noted compared with phosphate-buffered saline–treated mice. In
LDLR//low-density lipoprotein receptor Rag 1 double-knockout mice, sustained levels of plasma IK17-scFv
was achieved by Adv-IK17-scFv–mediated hepatic expression, which led to a 46% reduction (p  0.001) in en
face atherosclerosis compared with adenovirus-enhanced green fluorescent protein vector. Importantly, perito-
neal macrophages isolated from Adv-IK17-scFv treated mice had decreased lipid accumulation compared with
adenovirus-enhanced green fluorescent protein–treated mice.
Conclusions These data support an important role for SR-mediated uptake of OxLDL in the pathogenesis of atherosclerosis
and demonstrate that oxidation-specific antibodies reduce the progression of atherosclerosis, suggesting their
potential in treating cardiovascular disease in humans. (J Am Coll Cardiol 2011;58:1715–27) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.017The pathogenesis of atherosclerosis is complex and involves
the impact of many well-documented traditional risk fac-
tors. Among those, hypercholesterolemia plays a dominant
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Oxidation-Specific Antibodies Inhibit Atherosclerosis October 11, 2011:1715–27to the matrix of the intima, it is
generally thought that modifi-
cation(s) of low-density lipo-
protein (LDL) lead to its recog-
nition and unregulated uptake by
macrophage scavenger receptors
(SRs), resulting in cholesteryl es-
ter accumulation. Oxidized LDL
(OxLDL) is generally thought to
be one of these important mod-
ifications, and a variety of mac-
rophage SRs redundantly bind
OxLDL, including SR-A (I, II,
III), CD36, SR-B1 MARCO,
LOX-1, and others (1–3). Al-
though there is controversy about
their quantitative role in foam
cell formation, considerable evi-
dence supports important roles
for these receptors in atherogen-
esis (4–6). We have shown that
certain antibodies recognizing
oxidation-specific epitopes can
block the ability of OxLDL to be
taken up by macrophages. For
example, the natural immuno-
globulin (Ig)M antibody E06/
T15, which binds to the phos-
phocholine (PC) group of
oxidized but not native phospho-
lipids (7), blocks the binding and
uptake of OxLDL mediated by
CD36 and SR-B1 on macro-
phages (8–10). Indeed, marked
in vivo elevation of E06/T15
gM titers in cholesterol-fed low-density lipoprotein recep-
or knockout (LDLR/) mice, achieved by immunization
ith Streptococcus pneumoniae, which contains the same PC
pitope, ameliorated the progression of atherosclerosis (11).
imilarly, infusion of IgM T15 decreased lesion formation
n a vein graft model (12) and immunization with PC-
eyhole limpet hemocyanin, which also increased PC-
pecific antibodies that bound to OxLDL, also retarded
esion progression (13). These and other data (reviewed in
artvigsen et al. (14) suggest the hypothesis that enhanced
iters of antibodies that block OxLDL binding to macro-
hage SR should decrease foam cell formation and decrease
therosclerosis.
Immunization with antigens to increase titers of oxidation-
pecific antibodies initiates a cascade of immunologic responses
hat could affect lesion formation aside from the direct impact
f the humoral antibody responses. Furthermore, antibodies of
ifferent isotypes have different effector functions, such as the
bility to opsonize antigens and fix complement and also to
ind to different Fc receptors, which in turn differ in their
Abbreviations
and Acronyms
Adv  adenoviral
Adv-EGFP  adenovirus-
expressed enhanced green
fluorescent protein
Adv-IK17-scFv 
adenovirus-expressed IK17
single-chain Fv fragment
Cu-OxLDL  copper-
oxidized low-density
lipoprotein
HC  high cholesterol
Ig  immunoglobulin
IK17-scFv  IK17 single-
chain Fv fragment
LDL  low-density
lipoprotein
LDLR/  low-density
lipoprotein receptor
knockout
MDA-LDL 
malondialdehyde-modified
low-density lipoprotein
OxLDL  oxidized low-
density lipoprotein
PBS  phosphate-buffered
saline
PC  phosphocholine
PCR  polymerase chain
reaction
Rag1/  Rag 1
knockout
SR  scavenger receptoriological responses. Therefore, even though an oxidation-pecific antibody has the capacity to block OxLDL uptake in
itro, it does not rule out the possibility that its ability to inhibit
esion formation in vivo is due to other immunologic
roperties.
We previously reported the cloning of the first human
ntibody to OxLDL from a Fab antibody phage display
ibrary (15). The Fab antibody IK17 was shown to bind to
oth OxLDL and malondialdehyde-modified LDL (MDA-
DL) but not to native LDL or to unrelated antigens,
ncluding tetanus toxoid, chicken ovalbumin, type VI collagen,
nd calf thymus single-stranded DNA. The dissociation con-
tant (Kd) for IK17 was 3.7 108 mol/l calculated according
to Klotz plots. MDA-LDL and copper oxidized low-density
lipoprotein (Cu-OxLDL) were effective competitors, whereas
native LDL, native high-density lipoprotein, MDA-modified
bovine serum albumin, 4-hydroxynonenal-modified LDL (an-
other prominent epitope of OxLDL), MDA-polylysine, and
MDA-murine IgG did not compete. On Western blots after
sodium dodecylsulfate–polyacrylamide gel electrophoresis un-
der reduced conditions, IK17 bound extensively to the protein
moiety (apoB) of Cu-OxLDL and MDA-LDL, but not to
native LDL or native high-density lipoprotein. IK17 inhibited
the uptake of OxLDL by macrophages and also bound to
apoptotic cells and inhibited their phagocytosis by macro-
phages. Intravenously injected IK17 also was targeted to and
effectively imaged atherosclerotic lesions in vivo (15,16).
Because neither IK17-Fab nor IK-17 single-chain Fv frag-
ment (IK17-scFv) has immunologic properties of intact anti-
bodies other than their ability to inhibit uptake of OxLDL and
apoptotic by macrophages, we hypothesized that if mice
treated with these IK17 antibody fragments had reduced
atherosclerosis, this would support an important role for
SR-mediated uptake of OxLDL in the pathogenesis of
atherosclerosis.
Methods
A detailed description of selected methods is provided in the
Online Appendix.
Preparation of IK17-Fab and IK17-scFv. PREPARATION
OF IK17-FAB. Recombinant IK17-Fab was produced in
L21 (DE3) Escherichia coli cells (Invitrogen, Carlsbad,
alifornia) and purified using a goat anti-human Fab
ffinity column (Pierce, Rockford, Illinois) to 99% purity
s shown by Western blotting (15). Residual endotoxin was
emoved (to 99%) using TritonX 114 (Sigma-Aldrich, St.
ouis, Missouri) as previously described (17). The purified
K17-Fab fully retained its immunoreactivity to MDA-
DL and copper OxLDL (Cu-OxLDL), using chemilumi-
escent immunoassays described in the following, similar to
he parent antibody.
GENERATION OF IK17-SCFV AND ITS ADENOVIRAL VECTOR. A
full description of these procedures can be found in the
Online Appendix. In brief, to convert IK17-Fab into a
single-chain Fv fragment, 2 rounds of polymerase chain
reaction (PCR) were used to introduce a 7-amino acid
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ites for cloning. The coding region of IK17-scFv was
mplified by PCR and then subcloned into HindIII and
otI sites of the eukaryotic expression vector pSecTag2A
Invitrogen), which contains a mouse kappa signal sequence
or expression and secretion, and a c-myc tag, allowing
etection with an anti-myc antibody. The expression and
ecretion cassette of the IK17-scFv gene was isolated from
he pSecTag-IK17-scFv plasmid by a PCR reaction and
hen inserted into the EcoRV (blunt) site of the adenovirus
huttle plasmid pDeltaE1Z, which expresses the transgene
rom the cytomegalovirus promoter. The resulting adeno-
irus shuttle plasmid pDeltaE1Z-IK17 was cotransfected
ith E1-deleted adenovirus backbone genome JM17 DNA
nto HEK293 cells. Two to 3 weeks after cotransfection,
laques were isolated and amplified to examine the IK17-
cFv expression. Adenoviral vectors were then purified through
rounds of caesium chloride centrifugation, and titers were
easured in 2 ways: plaque formation on HEK293 cells
plaque-forming units per milliliter) and OD260 reading (par-
icles per milliliter). The enhanced green fluorescent protein
ene was inserted into the same adenoviral vector to generate
denovirus expressed enhanced green fluorescent protein
Adv-EGFP), which was used as a control.
urine models and atherosclerosis studies. Animal pro-
ocols were approved by the University of California San
iego and the Veterans Affairs Institutional Animal Care
nd Use Committee. All mice used were on the C57BL/6
ackground and included wild-type C57BL/6 (Jackson
aboratories, Bar Harbor, Maine), LDLR/, and LDL
eceptor Rag 1 double-knockout (LDLR//Rag1/)
mice (18). The mice were bred and maintained under
specific pathogen-free conditions unless otherwise noted.
STUDY 1: INFUSION OF IK17-FAB IN LDLR/ MICE. Twenty-
wo male LDLR/ mice (6 weeks old) were placed on a
1.25% cholesterol/21% milk fat diet for 2 weeks to rapidly
increase total cholesterol levels and to initiate atherosclerosis
and then switched to a normal mouse chow diet enriched
with 0.5% cholesterol for another 2 weeks as previously
described (19). This diet was then continued for the
remainder of the study, and the mice (n 11 in each group)
were randomized to receive either IK17-Fab (2.5 mg/kg in
sterile phosphate-buffered saline [PBS]) or similar volume
PBS, given intraperitoneally 3 times per week for 14 weeks.
Blood samples were obtained before the 1.25% cholesterol/
21% milk fat diet, before the 0.5% cholesterol diet, and then
at 4-week intervals until the end of the study (total of 6 time
points). The animals were then killed by CO2 inhalation, at
which time the extent of atherosclerosis was determined.
STUDY 2: ADENOVIRAL EXPRESSION OF IK17-SCFV IN C57BL/6
AND IN LDLR//RAG1/ MICE. In initial studies to validate
he ability of adenovirus expressed (Adv)-IK17-scFv to express
iologically active IK17 into plasma, we injected C57BL/6
ice with varying doses of virus and then measured IK17-scFviters in plasma as described in the following text. Biologicallyctive IK17-scFv was secreted into plasma, but sustained
xpression was not possible because of rapidly extinguished
epatic expression of IK17-scFv and because of murine hu-
oral responses to the human IK17. To overcome this, we
xpressed the Adv-IK17-scFv in LDLR//Rag1/ mice.
or gene transfer, 10-week-old male mice (20 to 25 g) were
nesthetized with 2% isoflurane inhalation, and adenoviral
ectors were diluted into 100 l of PBS and injected through the
etro-orbital plexus with a 27-gauge needle.
The male LDLR//Rag1/ mice were divided into 2
roups of 15 animals each. Group A was injected with 1011
viral particles of Adv-IK17-scFv and group B was injected with
the same amount of Adv-EGFP. One week after the first
injection, the mice were started on a high cholesterol (HC) diet
(Harlan-Teklad 8604 standard rodent diet containing 1.25%
cholesterol) for 16 weeks. These mice were subsequently
treated by repeat injections every 2 weeks. Blood (100 l)
as collected 2 weeks before the study and at 2, 4, 8, and 16
eeks after initiation of the HC diet. After 16 weeks of the
C diet, the mice were killed by CO2 inhalation, and the
entire aorta and heart were removed for atherosclerosis measure-
ments. Two of the mice injected with Adv-IK17-scFv died before
the end of the study, and their data are not included.
MACROPHAGE BINDING AND COMPETITION ASSAY. Bind-
ing of biotinylated Cu-OxLDL and MDA-LDL ligands to
J774 murine macrophages plated in microtiter wells and the
ability of IK17-Fab or IK17-scFv in culture supernatants or
plasma to inhibit binding were assessed by a chemiluminescent
binding assay as previously described (11,20) with modifica-
tions. A detailed protocol can be found in the Online Appendix.
PERITONEALMACROPHAGE ISOLATIONANDLIPID CONTENT
ASSESSMENT. Foam cell formation in elicited peritoneal
macrophages of experimental mice was determined as pre-
viously described (21). To derive mechanistic information
for study 2, in a separate experiment, LDLR//Rag1/
mice were treated with regular mouse chow, an HC diet, an
HC diet and Adv-IK17-scFv, or an HC diet and Adv-
EGFP every 2 weeks for 8 weeks. Peritoneal macrophages
were isolated from mice 4 days after intraperitoneal injec-
tion of thioglycolate. Cells 1.0  105 were resuspended into
0.5 ml of Dulbecco’s modified Eagle medium containing
20% fetal calf serum and added to each well of a 24-well
culture plate laid with a round cover slip. After the macro-
phages were attached to the cover slip (about 3 h), the cells
were washed with PBS and fixed with formaldehyde/sucrose
solution. The cells were then stained with heated Oil red
O/propylene glycol solution and mounted. The lipid-loaded
macrophages were counted using a microscope with a visual
grid and expressed as the percentage foam cells per total
cells counted.
CHEMILUMINESCENT IMMUNOASSAYS, IMMUNOHISTO-
CHEMISTRY, AND ATHEROSCLEROSIS QUANTIFICATION.
Methodologies for these assays are described in the Online
Appendix.
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Oxidation-Specific Antibodies Inhibit Atherosclerosis October 11, 2011:1715–27Statistical analysis. Differences between groups in athero-
sclerosis measures and immunohistochemistry parameters were
analyzed by Student t test. Analysis of quantitative parameters
f oxidation biomarkers within groups of mice over time (4
ime points) (Fig. 1B) and of the percentage of Oil Red O
taining (4 groups, Fig. 6B statistics) was performed with
epeated measures analysis of variance with post hoc Bonfer-
oni correction. p values 0.05 are considered significant. Data
re given as mean  SEM unless otherwise noted.
Figure 1 Impact of Injection of IK17-Fab on Atherosclerosis in
Plasma IK17-Fab concentrations (A) and IK17-Fab mouse immunoglobulin (Ig)G
significant (p  0.001; analysis of variance [ANOVA] with Bonferroni correction
IK17-Fab–injected LDLR/ mouse stained with Sudan IV. (D) Quantitative ana
percentage of Sudan IV stained area of entire aorta examined. conc  concen
knockout mice; RLU  relative light unit.esults
tudy 1: IK17-Fab infusion inhibits atherosclerosis
rogression in LDLR/ mice. There were no significant
differences in weight gain, plasma cholesterol, or triglyceride
levels between groups over time (Table 1). Significant
increases in autoantibodies to MDA-LDL, apoB-immune
complexes, and IgM T15/E06 levels occurred in both
groups in response to the diet, but no significant differences
/ Mice in Study 1
M immune complexes (B) in study 1. Increases in both IgM and IgG titers are
Representative aortic images from a phosphate-buffered saline control or
f en face atherosclerotic area in the entire aorta. Data are expressed as the
; IC  immune complex; LDLR/ mice  low-density lipoprotein receptorLDLR
or Ig
). (C)
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Appendix).
IK17-FAB PLASMA CONCENTRATIONS AND IK17-FAB IMMUNE
COMPLEXES. As expected, substantial elevations in plasma
evels of IK17-Fab concentrations were documented at 4 to
weeks during the ongoing IK17-Fab infusions. However,
K17-Fab plasma levels decreased significantly by the end of
he study (Fig. 1A), corresponding to an increase in titers of
urine IgG (31,140  8,198 vs. 335  105 relative light
nits, p 0.001) and IgM (17,140 3,397 vs. 2,009 262
elative light units, p  0.001) anti-IK17 antibodies in the
K17-Fab–injected group (data at 1:500 plasma dilution).
his was also associated with increased plasma levels of
urine IgM and IgG IK17-Fab/immune complexes
Fig. 1B).
IMPACT OF IK17-FAB ON ATHEROSCLEROSIS PROGRESSION.
Despite the immune response to IK17-Fab, there was a 29%
decrease in en face atherosclerosis in the IK17-treated
LDLR/ mice compared with mice treated with PBS (4.9
0.25% vs. 6.9 0.47%, p 0.001) (Figs. 1C and 1D). In fact,
the mice with the lowest anti-IK17 immune response also had
the least atherosclerosis, and for the group as a whole, the
plasma titers of IgG anti-IK17 antibodies correlated positively
with the extent of en face lesion formation in the IK17-Fab–
treated mice (Spearman correlation, r  0.87; p  0.001)
nalysis of cross sections at the level of the aortic valve did not
eveal differences between the 2 groups (1.93  0.20 mm2 vs.
2.12  0.13 mm2 total lesion area, p  0.42). Immunohisto-
chemistry of the aortic root for macrophages, smooth muscle
cells, collagen, and MDA epitopes revealed a strong trend (p
0.08) for reduced MDA staining but no differences in other
measures (Online Fig. 2).
Study 2: adenoviral expression of IK17-scFv inhibits
progression of atherosclerosis in LDLR//Rag1/
mice. To overcome the likely neutralization of the infused
IK17-Fab by mouse anti-IK17 antibodies, we generated
IK17 as a functional scFv and expressed it via an adenoviral
vector in LDLR//Rag1/ mice, which lack T and B
ells.
GENERATION OF FUNCTIONAL IK17-SCFV. IK17-scFv was
generated and purified to near homogeneity as described in
detail in the Online Appendix. Similar to the parent
IK17-Fab, the purified IK17-scFv displayed the same bind-
ing to OxLDL and MDA-LDL when examined by chemi-
luminescent enzyme-linked immunosorbent assay (Fig. 2A),
and inhibited the binding of both MDA-LDL (Fig. 2B) and
OxLDL (Fig. 2C) to J774 macrophages. Examination of
the binding of the IK17-scFv gene product from the
eukaryotic expression vector pSecTag2A (Fig. 2D) and the
adenovirus shuttle vector pDelta-E1Z revealed the same
binding properties as purified IK17-Fab. Furthermore, the
IK17-scFv recombinant adenovirus (Adv-IK17-scFv) res-
cued from 293 cells was infectious and cells infected with
Adv-IK17-scFv expressed and secreted IK17-scFv into theEf
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properties of the parent IK17-Fab (Fig. 2D).
THE ADENOVIRUS IK17-SCFV TRANSGENE WAS EXPRESSED
AND SECRETED INTO THE CIRCULATION. In an initial
Figure 2 Characterization of Adv-IK17-scFv Expression In Vitro
(A) Binding of purified IK17-Fab and IK17 single-chain Fv fragment (IK17-scFv) to malo
lipoprotein (Cu-OxLDL), but not to native LDL (Nat-LDL) or minimally modified LDL (mm
coated plates but IK17-Fab or IK17-scFv was detected with goat anti-human IgG Fab-A
(RLU)/100 ms. (B and C) Purified IK17-scFv inhibits the binding of Cu-OxLDL or MDA-
(B) or Cu-OxLDL (0.8 g/ml) (C) were incubated with freshly purified IK17-scFv at indi
tor (B) divided by binding in the absence of competitor (B0). (D) Binding properties of
culture medium of HEK293 cells infected with adenovirus-expressed IK17 single-chain
infection) and media from initial plaque (P1), and media from a single clone (C1) (all astudy, we injected 2.5  1011 viral particles of Adv-IK17- pcFv into wild-type C57B6 and LDLR//Rag/ mice
ia a tail vein and collected blood samples at 5, 19, and 28
ays post-injection. Functional IK17-scFv, detected by
inding to MDA-LDL and Cu-OxLDL, was detectable in
ehyde-modified low-density lipoprotein (MDA-LDL) and copper-oxidized low-density
The enzyme-linked immunosorbent assay (ELISA) was done on the same antigen-
ti–c-myc-AP, respectively. Extent of binding is expressed as relative light units
J774 macrophages. Fixed concentration (conc.) of biotinylated MDA-LDL (1.5 g/ml)
concentrations. Data are expressed as a ratio of binding in the presence of competi-
cFv gene products from the eukaryotic expression vector pSecTag2A and from the
gment (Adv-IK17-scFv). Shown are ELISAs to indicated antigens of control media (no
dilution). BSA  bovine serum albumin.ndiald
-LDL).
P or an
LDL to
cated
IK17-s
Fv fra
t 1:50lasma at day 5, but was lost after 19 days (Fig. 3A). Repeat
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October 11, 2011:1715–27 Oxidation-Specific Antibodies Inhibit AtherosclerosisFigure 3 Injection of Adv-IK17-scFv Delivers Functional IK17-scFv Into Mouse Plasma
(A) Enzyme-linked immunosorbent assay of plasma from wild-type C57BL/6 and the LDLR//Rag1/ mice at indicated time post-injection with 2.5  1011 viral parti-
cles of Adv-IK17-scFv. The binding to each antigen is the average of results from 2 mice from each group assayed, with all determinations in the same assay. Repeat
injections of Adv-IK17-scFv restored the expression of transgene in LDLR//Rag1/ mice, but not in C57BL/6 wild-type mice. (B and C) IK17-scFv plasma expression
in LDLR//Rag1/ mice throughout 16 weeks of gene transfer in study 2. Shown are binding to indicated antigens (in RLU/100 ms) using plasma (1:50 dilution)
from Adv-IK17-scFv or adenovirus-enhanced green fluorescent protein (Adv-EGFP)–injected mice 1 week post-injection with 1011 of indicated viral particles (B), as well as
the terminal blood after 16 weeks of a high-cholesterol diet and 9 biweekly injections (C). (D and E) Adv-IK17-scFv inhibits the binding of OxLDL to J774 macrophages.
Fixed concentration of biotinylated MDA-LDL (1.5 g/ml) (D) or Cu-OxLDL (0.8 g/ml) (E) were incubated with indicated dilutions of pooled plasma from adenovirus-injected
animals (graphed as reciprocals, e.g., 1/100  0.01). The y-axis indicates the biotinylated OxLDL bound to macrophages expressed as a ratio of binding in the presence of
competitor (B) divided by binding in the absence of competitor (B0). In D and E, BSA alone is used as a comparator. LDLR
//Rag1/  low-density lipoprotein receptor
Rag 1 double-knockout; other abbreviations as in Figures 1 and 2.
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the appearance of plasma IK17-scFv binding activity 7 days
later. We reasoned that the host immune response extin-
guished the adenoviral expression of IK17-scFv, both at the
level of the liver and by mounting an antibody response to
the human transgene. Indeed, we demonstrated murine IgG
and IgM titers to the IK17-scFv gene product from the
plasma 19 days post-injection of Adv-IK17-scFv in wild-
type LDLR/ mice (data not shown). To overcome this
roblem, we injected Adv-IK17-scFv into LDLR//
ag1/ mice. However, even in these mice that lack both
B and T cells, IK17-scFv expression in plasma was also
limited to 3 weeks, presumably due to methylation of the
cytomegalovirus promoter in the liver (21). However, in
these mice, repeated injections of Adv-IK17-scFv restored
the transgene expression each time for approximately 3
weeks (Fig. 3A).
SUSTAINED EXPRESSION OF IK17-SCFV FOR 16-WEEK
INTERVENTION STUDY. By repeatedly injecting Adv-IK17-
cFv at 2-week intervals, we maintained a sustained and
igh titer of IK17-scFv in plasma over a 16-week period.
sing real-time PCR to monitor tissue expression of the
njected transgene, we demonstrated that it was predomi-
antly expressed in liver as expected (Online Fig. 4). By
onitoring IK17-scFv binding to MDA-LDL and Ox-
DL by enzyme-linked immunosorbent assay, we demon-
Figure 4 Adv-IK17-scFv Immunostains Atherosclerotic Lesion
Pooled plasma (1:20 dilution) from Adv-IK17-scFv mice (A) or control adenovirus-e
human brain artery atherosclerotic lesion. Plasma samples were obtained from res
localizes to atherosclerotic lesions in the cholesterol-fed LDLR//Rag1/ mice
or with Adv-EGFP (D). Sections were obtained at time of killing and immunostainedtrated sustained expression of functional IK17-scFv in Tlasma throughout the 16 weeks of gene transfer (Figs. 3B
nd 3C). A competitive immunoassay demonstrated that
he binding of secreted IK17-scFv to both OxLDL and
DA-LDL was inhibited by both MDA-LDL and Ox-
DL, but not native LDL, indicating that the plasma
K17-scFv retained its specific binding properties (Online
ig. 5). Furthermore, the secreted IK17-scFv retained its
unctional property to inhibit the binding of MDA-LDL
nd OxLDL to macrophages (Figs. 3D and 3E). Serial
ilutions of plasma from mice injected with Adv–IK17-scFv
isplayed a dose-dependent inhibition of binding of MDA-
DL and OxLDL to J774 macrophages and at a dilution of
:40 completely abolished binding. This degree of inhibi-
ion was much greater than that observed with equivalent
ilutions of plasma from control mice injected with the
dv-EGFP vector. Although plasma of the Adv-EGFP
ice also showed a slight degree of inhibition, this also
ccurred in plasma from wild-type mice, which is in part
onspecific and in part due to plasma proteins that may bind
xLDL (data not shown).
PLASMA FROM ADV-IK17-SCFV INJECTED MICE IMMUNO-
STAINED ADVANCED ATHEROSCLEROTIC LESIONS. To dem-
nstrate that the secreted IK17-scFv could localize to
therosclerotic lesions, a 1:20 dilution of plasma from an
dv-IK17-scFv–injected mouse was used to immunostain
therosclerotic lesions from a human brain artery (Fig. 4).
ed green fluorescent protein (Adv-EGFP) mice (B) were used to immunostain
e mice 5 days post-injection. (C and D) demonstrate that the Adv-IK17-scFv
sections at the aortic valve obtained from mice treated with Adv-IK17-scFv (C)
biotinylated anti–c-myc. Abbreviations as in Figures 1 and 3.nhanc
pectiv
. Cross
withhe IK17-scFv preferentially stained the necrotic cores
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IK17-Fab (23). The same dilution of plasma from Adv-
EGFP–injected mice produced no specific immunostaining
(Fig. 4B). The secreted IK17-scFv also localized to its own
atherosclerotic lesions as documented at the time of killing
in aortic sections that were obtained from mice expressing
the Adv-IK17-scFv and immunostained for IK17-scFv
using an anti-myc antibody. There was specific localization
(brown areas) of IK17-scFv to atherosclerotic lesions (Fig. 4C).
In contrast, although there was light and diffuse staining of
tissue by plasma of Adv-EGFP mice, there was no specific
localization to the atherosclerotic lesions (Fig. 4D).
IMPACT OF PLASMA IK17-SCFV ON ATHEROSCLEROSIS. We
evaluated the impact of the secreted IK17-scFv on the
extent of atherosclerosis in the LDLR//Rag/ mice
uring a 16-week period of feeding the HC diet compared
ith mice receiving the Adv-EGFP vector under an iden-
ical protocol. Both groups of mice gained weight equally
nd had similar plasma cholesterol and triglyceride levels
uring the intervention period (Table 1). The extent of en
ace aortic lesion area was significantly reduced in the
dv-IK17-scFv–treated mice compared with the Adv-
GFP–treated mice (Fig. 5A), leading to a 46% reduction
n lesion area (2.1  0.3% vs. 3.9  0.4%, p  0.001)
Fig. 5B). Cross-sectional analysis at the aortic origin
evealed only small lesions and no statistically significant
ifference (0.27  0.05 mm2 vs. 0.23  0.06 mm2, total
lesion area, p  0.62).
EFFECT OF ADV-IK17-SCFV ON MACROPHAGE FOAM CELL
FORMATION. Previously, Li et al. (21) showed that the
extent of foam cell formation observed in elicited peritoneal
macrophages reflected the extent of foam cell formation
noted in the aorta of mice after various experimental
interventions. Therefore, we elicited peritoneal macro-
phages from Adv-IK17-scFv and Adv-EGFP mice, as well
as from LDLR//Rag1/ mice fed either chow or the
C diet. In contrast to macrophages isolated from mice
hat were fed a normal chow diet, macrophages isolated
rom hypercholesterolemic mice exhibited extensive Oil Red
droplets (Fig. 6A, chow-only diet and HC diet only).
acrophages from the Adv-IK17-scFv–treated mice
howed a marked reduction of lipid accumulation (Fig. 6A,
C diet  Adv-IK17-scFv) compared with macrophages
solated from the Adv-EGFP mice or the HC diet mice
Fig. 6A, HC diet only and HC diet  Adv-EGFP). We
lso quantified the number of macrophages showing lipid
roplets/100 cells counted. Macrophages isolated from
dv-IK17-scFv–treated mice had significantly fewer cells
ith lipid droplets compared with those from Adv-EGFP–
reated, or HC diet–fed nontreated LDLR//Rag1/
mice (36.8 7.2%, n 4 vs. 80.5 3.7%, n 3 or 77.2
.4%, n  4, p  0.0001) (Fig. 6B). This observation
uggests that the IK17-scFv significantly decreased foam
ell formation, consistent with the demonstrated ability of
he plasma of the IK17-scFv–treated mice to inhibit uptakef OxLDL by macrophages, as shown in Figures 3D
nd 3E.
iscussion
his study demonstrates that infusion of the IK17-Fab into
DLR/ mice inhibits atherosclerotic lesion formation.
Furthermore, expression of Adv-IK17 in vivo as a functional
single-chain antibody (IK17-scFv) also led to inhibition of
foam cell formation and decreased atherosclerosis. These
data support the hypothesis that a major mechanism by
which oxidation-specific antibodies inhibits atherosclerosis
is by blocking OxLDL binding to macrophages, supporting
an important role for SR-mediated uptake of OxLDL in the
pathogenesis of atherosclerosis. Furthermore, these results
suggest the potential of oxidation-specific antibodies in
treating cardiovascular disease in humans.
Although atherogenesis is a highly complex process, it is
strongly related to elevated plasma LDL cholesterol levels.
Once native LDL penetrates the intima, it binds to the
glycoprotein matrix, which prolongs its half-life and renders
it susceptible to a variety of modifications (1,24). Among
these, the generation of OxLDL has been widely studied
and considered important, as OxLDL is recognized by a
variety of SRs on macrophages, leading to unregulated
uptake. Indeed, although excellent experimental studies in
genetically targeted mice have supported the importance of
SR-A and CD36 in atherogenesis (25–27), other such
studies have provided opposing data and conclusions (6,28).
Aside from differences in experimental conditions (4), the
nature of the modified lipoprotein ligands for the SRs
induced by diet may be an important variable in such studies
(27). In addition, such SRs are innate “pattern recognition
receptors” and may well have other vital functions (14,29).
Deleting them via genetic targeting may have disrupted
other important properties involved in immunity and
atherogenesis, and/or led to unknown compensatory func-
tions that may complicate the interpretation of their impor-
tance in the uptake of OxLDL. Therefore, inhibiting the
uptake of OxLDL with oxidation-specific antibody frag-
ments lacking immunologic properties other than their
ability to recognize their respective epitopes allows one to
examine the importance of SR-mediated uptake of OxLDL
in atherogenesis.
We previously characterized IK17-Fab, the first cloned
human antibody to OxLDL (23). It binds to an epitope
different from that recognized by E06 (7), one contained on
both OxLDL and MDA-LDL, but like E06, it has the ability
to block the uptake and degradation of OxLDL by macro-
phages. To date, we have not fully characterized the exact
epitope to which IK17 binds, although it appears to be a
complex MDA-type structure, present in both the lipid and
protein moieties of OxLDL and MDA-LDL. Importantly,
IK17-Fab immunostains atherosclerotic lesions in mice,
rabbits, and humans, especially the necrotic core (23,30,31),
and has been used to successfully image lesion formation in
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relevant epitopes in lesions and would be strategically posi-
tioned to inhibit OxLDL uptake by macrophages in vivo.
Indeed, in this study, we demonstrated that either the passive
transfer of IK17-Fab to LDLR/ mice or the adenoviral-
ediated expression of IK17-scFv in LDLR//Rag1/
mice inhibited atherosclerosis progression. To our knowl-
edge, neither IK17-Fab nor the IK17-scFv has any immu-
nologic properties of intact antibodies other than the ability
to bind to oxidation-specific epitopes and thus inhibit
uptake of OxLDL by macrophages. Furthermore, they
achieve this inhibition by binding to SR ligands on OxLDL
and not by interfering directly with SR functions. We
believe that these data strongly support the hypothesis that
SR-mediated uptake of OxLDL plays an important role in
atherogenesis, particularly in the setting of the HC diet used
in these studies (28). Indeed, the demonstration that in vivo
foam cell formation in peritoneal macrophages was inhib-
ited by the expression of IK17-scFv provides direct evidence
to support this hypothesis.
In study 1, we injected purified lipopolysaccharide-free
IK17-Fab into LDLR/ mice. The impact of IK17-Fab
infusion was limited by the development of murine anti–
IK17-Fab antibodies during the latter part of the interven-
tion period, and, indeed, at the end of the study, the titer of
murine anti-IK17-Fab antibodies correlated directly with
lesion formation, suggesting that depletion of IK17-scFv
was associated with greater lesion formation. Despite these
limitations, lesion formation was inhibited by 29%, support-
Figure 5 Adv-IK17-scFv Reduces Atherosclerosis in LDLR//R
(A) Representative Sudan IV stained en face preparations of aortas from mice inje
atherosclerotic surface area in the entire aorta. Data expressed as the percentage
Abbreviations as in Figures 3 and 4.ing the hypothesis that macrophage SR uptake plays animportant role in early lesion formation. This conclusion
was strongly supported by the findings in study 2, in which
a biologically functional IK17-scFv was generated and
expressed in plasma for a period of 16 weeks. The IK17-
scFv is a linear protein in which the antigen-binding
domains of the antibody, the respective CDR3 regions of
the VH and VL genes, are joined by a short synthetic linker
hat allows appropriate folding of the expressed protein to
ffect the biological properties of the intact IK17-Fab.
K17-scFv lacks any of the effector properties of an intact
ntibody other than its ability to bind to its target epitope.
ustained expression of IK17-scFv was accomplished by
iweekly injections of Adv-IK17-scFv into LDLR//
ag1/ mice. Not only was en face lesion formation
nhibited substantially, by 46%, but foam cell formation was
nhibited in peritoneal macrophages isolated from these
ice. Inhibition of foam cell formation was not seen in
DLR//Rag1/ mice injected in an identical protocol
ith the same adenoviral vector but bearing the EGFP
ene.
It should be noted that in study 2 we maintained a
mall cohort of LDLR//Rag1/ mice on the same
HC diet but performed no interventions. The plasma
cholesterol levels in these mice were lower than in both
groups of Adv-injected mice and at time of killing, the
extent of atherosclerosis was similar to that of the mice
injected with the Adv-IK17-scFv. This suggests that the
repeated injections of adenovirus in this protocol in-
creased both plasma cholesterol levels and extent of lesion
/ Male Mice
ith Adv-IK17-scFv or Adv-EGFP. (B) Quantitative analysis of
dan IV stained area of the entire aorta examined.ag1
cted w
of Suformation. Because cholesterol levels of Adv-EGFP–
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throughout the study, this demonstrates that despite the
apparently increased atherogenic stress caused by the
repeated adenovirus administration, IK17-scFv decreased
lesion formation. Another caveat is that the IK17 inter-
ventions only decreased lesion formation in the en face
analyses and not at the aortic root. We do not know the
reasons for this. In our previous study with immunization
of LDLR/ mice with MDA-LDL, we observed the
opposite (i.e., decreased lesion formation at the aortic
root, but not distally). In those studies, we used a
high-fat, HC diet and plasma cholesterol levels exceeded
1,500 mg/dl. In the current studies, we used a
cholesterol-enriched diet that does not have any added
Figure 6 Adv-IK17-scFv Reduces Foam Cell Formation in Elicite
(A) Oil Red O staining of macrophages isolated from LDLR//Rag1/ mice fed
scFv or HC diet  Adv-EGFP treatment for 16 weeks as indicated. (B) Quantificatio
Abbreviations as in Figures 1 and 3.fat and produces more modest hypercholesterolemia and talmost devoid of very low density lipoprotein. High very
low density lipoprotein cholesterol levels observed in a
high-fat, HC diet have been associated with enhanced
lesion formation at the aortic origin (32). With the HC
diet used in our current study, we observed smaller lesions
at the aortic root, and, in particular, in the LDLR//
ag/ mice, the aortic root lesions were only 10% of
hose seen in the LDLR/ mice.
These studies not only provide evidence to support an
mportant role for SR uptake of OxLDL in macrophage
oam cell formation, but demonstrate the potential thera-
eutic efficacy of interventions that target OxLDL uptake
y macrophages, such as oxidation-specific antibodies or
ntibody fragments. We and others previously showed
ritoneal Macrophages
r chow, or high cholesterol (HC) diet only (nontreated), or HC diet  Adv-IK17-
acrophages that contained lipid droplets as a percentage of total cells counted.d Pe
regula
n of mhat increasing the titer of E06/T15 antibodies directed
a
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(11,13) or direct infusion (12) inhibited atherosclerosis
progression, and the current study and data of others (33,34)
have shown that direct infusion of a Fab or an IgG1 to
MDA-type oxidation-specific epitopes also limits lesion
formation.
In the current paper, we also show the feasibility of using
gene transfer techniques to deliver into plasma an antibody
fragment capable of influencing macrophage foam cell
formation. The adenovirus-encoding IK17-scFv produced a
significant level of transgene in the plasma 4 to 5 days
post-injection, which displayed the identical binding prop-
erties as its parental IK17-Fab (23). It maintained its ability
to bind and block the uptake of OxLDL by macrophages in
culture and immunostained oxidation-specific epitopes in
atherosclerotic lesions. Most importantly, it decreased foam
cell formation in peritoneal macrophages and substantially
inhibited the progression of atherosclerosis. Therefore, this
gene transfer experiment demonstrates that an scFv gene
can be delivered and expressed in tissues, leading to the
secretion into plasma of a biologically active antibody
fragment.
In our initial gene transfer experiment in wild-type
LDLR/ mice, there was the rapid extinguishing of the
denovirus-mediated expression of IK17-scFv, which we
hought secondary to adaptive immune responses. However,
e were surprised that the Adv-IK17-scFv was also rapidly
xtinguished after 2 weeks even in LDLR//Rag1/
mice, which lack adaptive responses. This most likely
involved inactivation of the cytomegalovirus promoter by
hypermethylation (22). If one were to apply such gene
transfer techniques to humans, the use of alternative pro-
moters and the use of fully human antibody fragments
would limit such inadequacies. The adenoviral vector used
in this study was selected to afford high titers to allow
demonstration of the feasibility of this approach, and
obviously more appropriate vectors would be needed for the
long-term expression in other animal models or in eventual
application to humans. The recent reports of the long-term
expression of gene products in humans using lentiviral
vectors (35,36) offers promise that one day vectors will be
developed that will allow safe and sustained gene transfer,
which could then be used to express antibodies such as the
IK17-scFv described in this report.
Study limitations. Immunohistochemistry was performed
only in the aortic root where the lesions were very small and
there were no differences in treatment effect in the extent of
atherosclerosis. Because the remaining aorta was used for
extensive processing for Sudan staining and en face athero-
sclerosis quantitation, it was not available for immunohis-
tochemical analyses to assess differences in cellular, matrix,
and oxidation-specific epitope content in regions of the
aorta where a treatment effect was present. Future studies
will focus on changes in plaque characteristics and athero-
sclerosis regression in response to human oxidation-specific
antibodies.Conclusions
Our data demonstrate the feasibility of direct infusion of
human oxidation-specific antibodies to inhibit lesion uptake
of OxLDL by macrophages, which presumably plays an
important role in macrophage activation and participates in
the induction of macrophage apoptosis and death
(30,37,38). Oxidation-specific antibodies such as IK17 and
E06 have recently been shown to strongly immunostain
human vulnerable and ruptured plaques (30). Oxidized
phospholipids are also released from clinically relevant
human lesions in significant quantities and can be captured
by distal protection devices after percutaneous coronary and
carotid interventions (39). One might envision the infusion
of oxidation-specific antibodies in the setting of unstable or
acute coronary syndromes to rapidly stabilize plaques or use
before percutaneous coronary, carotid, and peripheral inter-
ventions to neutralize released proinflammatory oxidized
lipids (40). In addition, these experiments provide a tem-
plate for using the biologically functional scFv as a reagent
targeting the vulnerable plaque for imaging approaches or to
mediate delivery of therapeutic agents or drugs (15,16). If
this approach is translated to humans, we anticipate its
initial application to be by direct infusion of an appropriate
dose of the antibody, similar to other antibody therapeutics
for inflammatory conditions and cancer treatment. Finally,
one might also envision a therapeutic approach leading to a
more sustained elevation of titers of oxidation-specific
antibodies, which could be accomplished by a variety of
techniques, including gene transfer techniques, once safe
and effective vectors are developed as well as the use of
vaccine approaches.
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